INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning posted a business update and reported financial results for the first quarter ended March 31, 2019. Among other highlights, the company summarized its corporate accomplishments for the quarter including its achievement of … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Posts Q1 2019 Financial Results, Issues Shareholder Update”
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced the close of its offering of 460,545 shares of common stock sold at a price of $9.00 each resulting in proceeds of $4,144,900. In addition to existing investors, such as CEO … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Closes $4.1M Private Placement”
INmune Bio (NASDAQ: INMB) this morning announced that Christopher Barnum, Ph.D., Director of Neuroscience and Translational Medicine, will be presenting a poster at the Neuroimmunology Drug Development Summit taking place in Boston on April 17th. The poster presentation is titled “Phase 1b open-label, biomarker-directed study of the brain penetrant, soluble selective inhibitor of soluble tumor … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Announces Poster Presentation at the Neuroimmunology Drug Development Summit in Boston”
INmune Bio (NASDAQ: INMB) this morning announced that the company’s co-founder and CEO Dr. RJ Tesi will be presenting at the Cambridge Healthtech Institute’s Inflammation Inhibitors Conference on April 11th at 4:50 PM in San Diego. Dr. Tesi’s presentation titled, “Targeting Soluble TNF to Eliminate Chronic Inflammation without Immunosuppression,” will discuss targeting soluble tumor necrosis … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) CEO to Present at the Cambridge Healthtech Institute’s Inflammation Inhibitors Conference”
INmune Bio (NASDAQ: INMB) this morning announced that Lesley Probert, Ph.D., Head of Immunology Department at the Hellenic Pasteur Institute in Athens, Greece, will be presenting a poster about new data on INmune’s neurodegenerative disease drug candidate XPro1595 at The European Conference on Neuroinflammation on April 8th and 9th. The presentation is titled “Selective inhibition … Continue reading “NetworkNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) XPro1595 Featured in Poster Presentation at The European Conference on Neuroinflammation”
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that various management team members including CEO Raymond J. Tesi, CFO David Moss and chief scientific officer Professor Mark Lowdell will ring the NASDAQ closing bell on Tuesday, April 9, 2019. … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Management Team to Ring the NASDAQ Closing Bell on April 9”
INmune Bio (NASDAQ: INMB) this morning announced that the company’s co-founder and CEO, Dr. R.J. Tesi, presented at Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit Europe 2019 on March 18th in London. Dr. Tesi’s presentation, titled, “Targeting Myeloid-Derived Suppressor Cells to Overcome Resistance to Checkpoint Inhibitors,” highlighted how combination therapy with the company’s drug candidate … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) CEO Presents at the 4th Annual Immuno-Oncology Summit Europe 2019 in London”
Inmune Bio (NASDAQ: INMB) is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack … Continue reading “Inmune Bio Inc. (NASDAQ: INMB) Attends 31st Annual ROTH Conference”
INmune Bio (NASDAQ: INMB) this morning announced that the company’s co-founders, R.J. Tesi, M.D., and Mark Lowdell, Ph.D., are presenting at the World Immunotherapy Congress USA during the Festival of Biologics San Diego, taking place from March 3rd to 5th. Dr. Tesi and Dr. Lowdell serve as the company’s chief executive office and chief scientific … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at the World Immunotherapy Congress in San Diego”
INmune Bio (NASDAQ: INMB) this morning announced that the company has been awarded a grant to receive $1,000,000 from the Alzheimer’s Association to advance XPro1595 under the Part the Cloud to RESCUE grant. XPro1595 is a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease. The award will be paid to the company in … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Granted $1M by the Alzheimer’s Association to Advance Development of XPro1595”
